Home Hemodialysis Improves Dialysis Patients Survival
By HospiMedica International staff writers Posted on 06 Nov 2018 |
Image: Performing renal hemodialysis at home ups survival (Photo courtesy of NxStage).
A new study reveals that more frequent home hemodialysis (HHD) provides significant improvements in first-year survival in renal dialysis patients across all age ranges.
The study, conducted by researchers at NxStage Medical (Lawrence, MA, USA), analyzed United States Renal Data System (USRDS) data for 557,139 incident dialysis patients who were prescribed more frequent HHD with the NxStage System One, or conventional in-center hemodialysis (IHD) therapy, shortly after dialysis initiation. The researchers estimated hazard ratios of death for HHD versus IHD, with adjustment for age, race, sex, primary cause of end-stage renal disease, comorbid conditions, vascular access type, body mass index (BMI), estimated glomerular filtration rate (eGFR), and hematocrit.
The results revealed that HHD patients were younger, more likely white, more likely male, less likely enrolled in Medicaid, and less likely to have heart failure (HF). Patients who initiated more frequent HHD showed improved survival, with a 23% lower risk of death versus IHD overall. The most striking results were found in patients in the 20-44 years age group, who experienced a 44% lower risk of death. The study was presented at the American Society of Nephrology (ASN) Kidney Week Conference, held during October 2018 in San Diego (CA, USA).
“Less than one percent of new dialysis patients each year perform home hemodialysis,” said lead author and study presenter Eric Weinhandl, PhD, clinical epidemiologist and biostatistician at NxStage. “44% lower risk of death is very meaningful, as younger dialysis patients have indicated that they place higher value on life expectancy. For young adults, maintaining both cardiovascular health and personal responsibilities and vocations are important, and increased hemodialysis frequency may be critical in improving both their clinical and quality of life outcomes.”
The NxStage System One is designed to deliver hemodialysis, hemofiltration, and/or ultrafiltration therapies to patients with renal failure or fluid overload. System features include a highly automated design with a drop-in cartridge to facilitate operation; high-quality premixed treatment fluids to enable fluid purity without relying on local water treatment; and wide operating ranges allow clinician flexibility in patient therapy prescriptions.
Related Links:
NxStage Medical
The study, conducted by researchers at NxStage Medical (Lawrence, MA, USA), analyzed United States Renal Data System (USRDS) data for 557,139 incident dialysis patients who were prescribed more frequent HHD with the NxStage System One, or conventional in-center hemodialysis (IHD) therapy, shortly after dialysis initiation. The researchers estimated hazard ratios of death for HHD versus IHD, with adjustment for age, race, sex, primary cause of end-stage renal disease, comorbid conditions, vascular access type, body mass index (BMI), estimated glomerular filtration rate (eGFR), and hematocrit.
The results revealed that HHD patients were younger, more likely white, more likely male, less likely enrolled in Medicaid, and less likely to have heart failure (HF). Patients who initiated more frequent HHD showed improved survival, with a 23% lower risk of death versus IHD overall. The most striking results were found in patients in the 20-44 years age group, who experienced a 44% lower risk of death. The study was presented at the American Society of Nephrology (ASN) Kidney Week Conference, held during October 2018 in San Diego (CA, USA).
“Less than one percent of new dialysis patients each year perform home hemodialysis,” said lead author and study presenter Eric Weinhandl, PhD, clinical epidemiologist and biostatistician at NxStage. “44% lower risk of death is very meaningful, as younger dialysis patients have indicated that they place higher value on life expectancy. For young adults, maintaining both cardiovascular health and personal responsibilities and vocations are important, and increased hemodialysis frequency may be critical in improving both their clinical and quality of life outcomes.”
The NxStage System One is designed to deliver hemodialysis, hemofiltration, and/or ultrafiltration therapies to patients with renal failure or fluid overload. System features include a highly automated design with a drop-in cartridge to facilitate operation; high-quality premixed treatment fluids to enable fluid purity without relying on local water treatment; and wide operating ranges allow clinician flexibility in patient therapy prescriptions.
Related Links:
NxStage Medical
Latest Critical Care News
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia
- AI-Driven Prediction Models Accurately Predict Critical Care Patient Deterioration
- Preventive PCI for High-Risk Coronary Plaques Reduces Cardiac Events